Patient Portal

Timothy Miller, MD, PhD

David Clayson Professor of Neurology
Neuromuscular Division

Specialty Areas

Neurology - Adult
ALS - Lou Gehrig's Disease
Neuromuscular Disease

Board Certifications

Neurology
Psychiatry

Hospital Affiliations

Barnes-Jewish Hospital

Languages

French

Areas of Clinical Interest

ALS and neurological disorders

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine
Neuroscience Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: 314-362-6981
Fax: 314-362-3752

Education

Education

Medical Degree: Washington University School of Medicine, St. Louis, MO 1998
PhD: Washington University School of Medicine, St. Louis, MO 1998
Residency: Neurology, University of California, San Francisco 2003
Fellowship: Neuromuscular, University of California, San Francisco 2003
BS, BA: University of Virginia, Charlottesville, VA 1991

Publication & Research

Publication & Research

1.    Gertsman I, Wuu J, McAlonis-Downes M, Ghassemian M, Ling K, Rigo F, Bennett F, Benatar M, Miller TM, Da Cruz S. An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamics monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight.2019. https://insight.jci.org/articles/view/122768

Ly, CV, Koenig L, Christensen J, Gordon B, Beaumont H, Dahiya S, Chen J, Su Y, Nelson B, Jockel-Balsarotti J, Drain C, Jerome G, Morris JC, Fagan AM, Harms MB, Benzinger TLS, Miller TM, Ances BM. Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. Eur J Neurol. 2019. https://onlinelibrary.wiley.com/doi/full/10.1111/ene.13940
Self WK, Schoch KM, Alex J, Barthelemy N, Bollinger JG, Sato C, Cole T, Kordasiewicz HB, Swayze E, Bateman RJ, Miller TM. Protein production is an early biomarker for RNA-targeted therapies. Annals of Clinical and Translational Neurology. 2018
Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Current Opinion in Neurology. 2018 Oct; 31(5):648-654
Hoye ML, Regan MR, Jensen LA, Lake AM, Reddy LV, Vidensky S, Richard JP, Maragakis NJ,  Rothstein JD, Dougherty JD, Miller TM. Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain. 2018. awy182, https://doi.org/10.1093/brain/awy182
McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Thankamony S, Salzman DW, Cudkowicz M, Graham DL, Bennett CF, Kordasiewicz HB, Swayze EE, Miller TM. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clinical Invest. 2018;128(8)
Hoye ML, Archambault AS, Gordon TM, Oetjen LK, Cain MD, Klein RS, Crosby SD, Kim BS, Miller TM, Wu GF. MicroRNA signature of central nervous system-infiltrating dendritic cells in an animal model of multiple sclerosis. Immunology. 2018
 Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O’Brien DR, Miller RL, Cole T, Schoch KM, Shen T, Kunikata T, Richard JP, Gutmann DH, Maragakis NJ, Kordasiewicz HB, Dougherty JD, Miller TM. microRNA profiling reveals marker of motor neuron disease in ALS models. J Neurosci. 2017 May 31; 37(22):5574-5586. PMID: 28416596.
DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Kordasiewicz HB, Tran H, Nichols B, Zanardi TA, Swayze EE, Bennett CF, Diamond MI, Miller TM. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine. 2017 Jan;9(374). PMID: 28123067.

1.    Gendron TFChew JStankowski JNHayes LRZhang YJPrudencio MCarlomagno YDaughrity LMJansen-West KPerkerson EAO'Raw ACook CPregent LBelzil Vvan Blitterswijk MTabassian LJLee CWYue MTong JSong YCastanedes-Casey MRousseau LPhillips VDickson DWRademakers RFryer JDRush BKPedraza OCaputo AMDesaro PPalmucci CRobertson AHeckman MGDiehl NNWiggs ETierney MBraun LFarren JLacomis DLadha SFournier CNMcCluskey LFElman LBToledo JBMcBride JDTiloca CMorelli CPoletti BSolca FPrelle AWuu JJockel-Balsarotti JRigo FAmbrose CDatta AYang WRaitcheva DAntognetti GMcCampbell AVan Swieten JCMiller BLBoxer ALBrown RHBowser RMiller TMTrojanowski JQGrossman MBerry JDHu WTRatti ATraynor BJDisney MDBenatar MSilani VGlass JDFloeter MKRothstein JDBoylan KBPetrucelli L. Poly(GP) proteins are a useful pharmacodynamics marker for C9ORF72-associated amyotrophic lateral sclerosis.Sci Transl Med. 2017. https://stm.sciencemag.org/content/9/383/eaai7866


1.    Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI. Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron. 2016 Nov;92(4):796-812. PMID: 27974162.


Ba   Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM. Defining SOD1 ALS Natural History to Guide Therapeutic Clinical Trial Design. Journal of Neurology, Neurosurgery and Psychiatry. 2016 June; E-pub ahead of print. PMID: 27261500


Sc   Shoch K, DeVos S, Miller R, Chun S, Norrbom M, Wozniak D, Dawson H, Bennett C, Rigo F, Miller TM. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron. 2016 June;90(5):941-947. PMID: 27210553


 1.    O'Rourke JG, Bogdanik L, Yáñez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016 Mar;351(6279):1324-1329. PMID: 26989253. 


 Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, Miller TM, Urano F.Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum Mol Genet. 2016. https://doi.org/10.1093/hmg/ddw052




Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N, Cudkowicz M, Miller TM. Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015 Sep;52(3):339-343. PMID: 25900666

1.   


Crisp MJ, Mawuenyega KG, Patterson BW, Reddy NC, Chott R, Self WK, Weihl CC, Jockel-Balsarotti J, Varadhachary AS, Bucelli RC, Yarasheski KE, Bateman RJ, Miller TM. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. The Journal of Clinical Investigation 2015;125(7):2772-2780. PMID: 26075819

Reddy LV, Miller TM. RNA-targeted Therapeutics for ALS. Neurotherapeutics 2015;12(2):424-427. PMCID: 4404448

Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014;82(6):1271-1288. PMCID: 4171396

Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 2014;71(4):449-453. PMCID: 4087113

Crisp MJ, Beckett J, Coates JR, Miller TM. Canine degenerative myelopathy: biochemical characterization of superoxide dismutase 1 in the first naturally occurring non-human amyotrophic lateral sclerosis model. Exp Neurol 2013;248:1-9. PMCID: 3773294



Areas of Research Interest

Innovative treatments, with a focus on therapeutic strategies that turn off harmful genes in the brain and spinal cord in patients with neurodegenerative diseases.